ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
ARISTOCRAT is a phase II, multi-centre, double-blind, placebo-controlled, randomised trial to
compare the cannabinoid Sativex with placebo in patients with recurrent MGMT methylated
glioblastoma (GBM) treated with temozolomide (TMZ).